Topic outline

  • General

  • Topic 1

    Adoption of Directive 2011/62 on falsified medicinal productst
    Dr Alexander Natz
    Adoption of Directive 2011/62 on falsified medicinal products

    This presentation covers delegated acts as referred to in Art. 290 (1) TFEU and gives details on its process of adoption. It shows the crucial role of delegated acts in the framework of the EU pharmaceutical legislation. It also tries to give answers to the question if an impact assessment or a consultation is legally mandatory for delegated acts. The process is illustrated by a practical example in the field of falsified medicinal products where in adopting delegated acts under Directive 2011/62 the European Commission involves stakeholders.
    Duration: 35 minutes
    Click here to start the e-presentation

    If you have any questions or encounter some technical difficulties please do not hesitate to contact us.                   Webmaster:Jochen Böhm